Thirty-four patients with advanced soft tissue sarcomas were entered in a phase II trial of echinomycin. Patients received 1.2 mg/m 2 intravenously (i.v.) weekly times four followed by a two week rest period. There were no objective responses. Dose limiting toxicity was gastrointestinal. Echinomycin
β¦ LIBER β¦
Phase II trial of merbarone in soft tissue sarcoma
β Scribed by Eric H. Kraut; Jackie Bendetti; Stanley P. Balcerzak; James H. Doroshow
- Publisher
- Springer US
- Year
- 1992
- Tongue
- English
- Weight
- 190 KB
- Volume
- 10
- Category
- Article
- ISSN
- 0167-6997
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
Phase II trial of echinomycin in advance
β
Sarah A. Taylor; Barbara Metch; Stanley P. Balcerzak; Karl H. Hanson
π
Article
π
1990
π
Springer US
π
English
β 232 KB
Phase II trial of trimetrexate in patien
β
Jonathan D. Licht; RenΓ© Gonin; Karen H. Antman
π
Article
π
1991
π
Springer
π
English
β 241 KB
A phase II clinical trial of echinomycin
β
William J. Gradishar; Nicholas J. Vogelzang; Lary J. Kilton; Steven J. Leibach;
π
Article
π
1995
π
Springer US
π
English
β 285 KB
Phase II trial of piroxantrone for advan
β
Mark M. Zalupski; Jacqueline Benedetti; Stanley P. Balcerzak; Laura F. Hutchins;
π
Article
π
1993
π
Springer US
π
English
β 390 KB
A phase II trial of PALA+dipyridamole in
β
Ephraim S. Casper; Jose Baselga; Tracy B. Smart; Gordon B. Magill; Maurie Markma
π
Article
π
1991
π
Springer
π
English
β 455 KB
Phase II trial of cisplatin (CPDD) in pr
β
Joseph Brenner; Gordon B. Magill; Peter P. Sordillo; Edgar W. Cheng; Allan Yagod
π
Article
π
1982
π
John Wiley and Sons
π
English
β 249 KB
π 3 views
Thirty-six previously treated adult patients with advanced soft tissue sarcomas received CPDD 120 mg/m2 with mannitol diuresis. There were only two (6%) partial responses and five (15%) minor responses in 34 evaluable patients. Toxicity included nausea and vomiting, myelosuppression, mild ototoxicit